TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: subjective satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: NEDV (Normalized End-Diastolic Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: EDV (End-Diastolic Volume)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement of total SODA score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FDG uptake of primary tumours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sensitivity, specificity and overall accuracy of FDG‐PET
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: treatment outcome and patient survival
Endpoint domain: Mortality/survival
Primary endpoint: Intraocular Pressure (IOP) at 5 hours after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Intraocular Pressure (IOP) at 1 day after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Rate of eradication of varices
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fever incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Passive postoperative flexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: therapeutic effect of rinses with antimicrobial ingredients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: unnecessary recall rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interobserver agreement for embryo classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraobserver reproducibility for embryo classification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: headache relief at 4 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Critical usage decisions
Endpoint domain: Life impact
Endpoint subdomain: Decision making
Primary endpoint: Root canal cleanliness (RPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum nausea score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of tumor necrosis factor (TNF‐α)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Superoxide dismutase (SOD) activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: haemagglutination inhibition (HI) titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: neutralization (NT) titres
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: cross-reactive CD4+ T-cell responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: short-term seroprotection (anti-PRP ≥ 0.15 μg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: long-term seroprotection (anti-PRP ≥ 1 μg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: overall local pain
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of A. actinomycetemcomitans in subgingival plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean infusion rate of rocuronium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spontaneous recovery duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total postoperative blood loss during the first 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for allogeneic blood transfusion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: 9-protein derived risk score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in plasma concentrations of proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in endocrine systems (aldosterone function and glycemic control)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: hypoglycaemia (<2.6 mM) in the first 48 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anesthesia grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Withdrawn bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy eating index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: School contentment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of screen failures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postoperative daily pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean weight change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive and Negative Syndrome Scale total score mean change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stroop test performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: incidence of side-effects
Endpoint domain: Adverse events/effects
Primary endpoint: hallucinations
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of aspiration during swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gait variability at preferred walking speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: fall frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of grade 3 or higher neutropenia
Endpoint domain: Adverse events/effects
Primary endpoint: surgeon preference rating
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: 8-week mean estimated caloric expenditure levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: minutes per week in MOD+ activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-management skills
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in necroinflammatory activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in bridging fibrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variations in mental development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Daytime symptoms of heartburn
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daytime epigastric pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healing rates of oesophagitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported social and test anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Unplanned target vessel revascularisation (TVR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: reduction in overall tic symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease-specific overall survival
Endpoint domain: Mortality/survival
Primary endpoint: maximum treatment-related morbidity
Endpoint domain: Adverse events/effects
Primary endpoint: Achieving daily intake of 200 ml of whole CM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of visual acuity of 15 letters or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Loss of visual field
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Lower risk of W.H.O./I.S.U.P. grade group ≥2 P.C.a
Endpoint domain: Mortality/survival
Primary endpoint: Forced expiratory flow at 25‐75% of the pulmonary volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Exhaled nitric oxide values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Evaluability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ungradable image rate for non-mydriatic photography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ungradable image rate for mydriatic photography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: risk recall and recognition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: benefit recognition
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: perceived risk severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: hs-CRP concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: interleukin-6 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvements in the Fugl‐Meyer Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvements in the Motor Activity Log
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone resorption (serum cross‐linked C‐telopeptide of type I collagen)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: Bone alkaline phosphatase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Bone and connective tissue outcomes
Primary endpoint: Treatment success rate for head louse infestation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pressure Pain Threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ultrasound Muscle Architecture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in MRB score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of technical complications
Endpoint domain: Adverse events/effects
Primary endpoint: PSS-10 scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Opsonophagocytic activity against serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: High‐avidity serotype‐specific IgG antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improvement of severity of shoulder pain and disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness of manipulative therapy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Arterial oxygen saturation (SpO(2))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Sodium excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: average attacks/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: attack symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Participation rates in an online health survey
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Serum MT1-MMP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone turnover markers (BAP, NTX)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in attitudes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of major complications in undernourished cirrhotic patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bile reflux into the esophagus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Weight gain after seven days of feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of prescribed feed received
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Burden of obesity rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Influence of obesity on daily life rating
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Functional Pain Score (FPS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement of sensory function and motor nerve function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amplitude of motor conduction of deep peroneal nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amplitude of sensory conduction of surficial peroneal nerve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Vo(2 peak) (max)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: durable recovery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum apo A‐I level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum HDL cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum PON activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of symptoms developed
Endpoint domain: Adverse events/effects
Primary endpoint: hepatic fat fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Affective arousal
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mean number of wake bouts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of toothbrushing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hardness of GIC after placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial circulating TAG concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: TNFalpha secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IL-6 secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Analgesic effect of bromfenac relative to ibuprofen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Human Insecurity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Concealed hernias detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: neonatal blood glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of neonatal hypoglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: length of neonatal hospital stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Intraocular Pressure (IOP) in the fellow eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: reduction of variceal rebleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: enhanced survival
Endpoint domain: Mortality/survival
Primary endpoint: Serum nutritional parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of sessions needed for evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Seizures
Endpoint domain: Adverse events/effects
Primary endpoint: McGill pain score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of corneal epithelium defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of fracture-related hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Cumulative risk of recurrence with P. vivax at 9 weeks
Endpoint domain: Mortality/survival
Primary endpoint: Risk of recurrent HELLP exacerbation
Endpoint domain: Mortality/survival
Primary endpoint: Platelet count recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Pouch mucosal functioning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of motor block at the elbow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep onset latency (SOLobj)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: sleep efficiency (SEsubj)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: number of hypoglycemic episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: tDCS tolerability
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of postpartum hemorrhage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kidney function (glomerular filtration rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neutropenia grade 3-4
Endpoint domain: Adverse events/effects
Primary endpoint: Paresthesia grade 1 or 2
Endpoint domain: Adverse events/effects
Primary endpoint: Sensory motor impairment grade 2
Endpoint domain: Adverse events/effects
Primary endpoint: Mean peak A wave velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak filling velocities of the left atrial appendage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Peak emptying velocities of the left atrial appendage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Need for homologous blood transfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Abstinence at 1 and 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urge-to-smoke frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eyelid edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Eyelid ecchymosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: improvement in sitting ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma concentrations of DHA and EPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decreased secretion of IL-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decreased secretion of IL-1beta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Peak concentrations (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration‐time curve (AUC) from 0 to 8 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MCQ score improvements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: final assessment scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of correct recall on consent quiz
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Central clearance (Cl(c)) of remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half life (t1/2 ss) of remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentrations of remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement in grading acute MCL injuries
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: OAB questionnaire HRQOL
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 24-hour frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: urge incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: erythrocyte glutathione peroxidase activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower incidence of atrial mechanical stunning
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VQ-Dermato Global Index score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: RBL change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: O2 saturation over 5 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: palpitations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: accelerated heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Asthma severity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AChE activity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes